Pfizer mRNA Influenza Vaccine ‘Failed’ in Clinical Trial Among Seniors: FDA Commissioner

‘We’re not just going to rubberstamp new products that don’t work, that fail in a clinical trial,’ Dr. Marty Makary said.

A woman wears a facemask as she walks by the Pfizer world headquarters in New York City on Nov. 9, 2020. (Photo by Kena Betancur / AFP) Photo by KENA BETANCUR/AFP via Getty Images

Pfizer’s experimental influenza vaccine will not receive approval absent new data proving that it protects seniors against the flu, the commissioner of the Food and Drug Administration suggested in a new interview.

The messenger ribonucleic acid (mRNA) shot “failed in seniors,” Dr. Marty Makary, the FDA commissioner, said during an appearance on Nov. 29 on Fox News.